Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
11/21/202/: Graybug merger confirmed!
“Graybug and CalciMedica Enter into Definitive Merger Agreement
Mentioned: GRAY
Graybug and CalciMedica Enter into Definitive Merger Agreement
-- Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing CalciMedica's pipeline of first-in-class product candidates for life-threatening inflammatory diseases
-- Combined company is expected to be funded with cash and cash equivalents of approximately $35 million at closing, with an expected runway into the second half of 2024
-- Phase 2b results in acute pancreatitis for lead product candidate Auxora expected in second half of 2023
-- Companies will host joint webcast on November 22, 2022, at 8:00 a.m. Eastern Time
REDWOOD CITY, Calif. and LA JOLLA, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY) (Graybug) and CalciMedica Inc. (CalciMedica) today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on further developing CalciMedica's lead product candidate Auxora(TM), a proprietary, intravenous-formulated, small molecule calcium-release activated calcium (CRAC) channel inhibitor, to treat life-threatening inflammatory diseases, such as acute pancreatitis (AP), asparaginase-associated pancreatitis (AAP), acute kidney injury (AKI), and acute hypoxemic respiratory failure (AHRF), for which there are no currently approved therapies. Auxora, which modulates the immune response and protects against tissue cell injury, has been studied in four completed efficacy clinical trials, demonstrating positive and consistent clinical results, as well as a favorable safety profile. Subject to each company's stockholder approval, the combined company is expected to trade on the Nasdaq Global Market.
With approximately $35 million in cash and cash equivalents anticipated from the combined company, including a private placement financing expected to occur immediately prior to the merger closing, the combined company is expected to have a cash runway into the second half of 2024, funding the advancement of Auxora in AP and AAP through clinical milestones in 2023. The proposed merger is expected to close in the first quarter of 2023.
"After completing a comprehensive strategic review, we determined that the proposed merger with CalciMedica would provide the best return for Graybug stockholders moving forward," said Frederic Guerard, Pharm.D., Chief Executive Officer of Graybug. "The decision by our management and board of directors to select CalciMedica to be our merger partner will allow our stockholders to participate in a company with a strong clinical-stage pipeline poised to revolutionize treatment for large, underserved patient populations suffering from life-threatening inflammatory diseases worldwide."
The combined company plans to advance the development of Auxora through multiple clinical trials and anticipates the following milestones in 2023:
-- Results from an ongoing Phase 2b clinical trial (CARPO) in AP patients with systemic inflammatory response syndrome (SIRS) in second half of 2023 -- CARPO is a randomized, double-blind, placebo-controlled, dose-ranging trial intended to establish efficacy in AP. It is expected to enroll 216 patients. AP can be a life-threatening condition where the pancreas becomes inflamed, sometimes leading to pancreatic cell death or necrosis, systemic inflammation, and organ failure. There are an estimated 275,000 hospitalizations for AP annually in the United States, of which approximately 40% present with SIRS, which can compromise the function of other tissues or organs, including the lungs, and is responsible for much of the mortality seen in AP. Details of the CARPO trial are available on clinicaltrials.gov (NCT04681066). -- Results from an ongoing investigator-sponsored Phase 1/2 clinical trial (CRSPA) in pediatric patients who develop AAP as a result of treatment with asparaginase for their underlying acute lymphoblastic leukemia (ALL) in first half of 2023 -- CRSPA is a Phase 1/2 trial being conducted in pediatric patients with AAP, which is acute pancreatitis resulting from the administration of asparaginase. Treatment with asparaginase triggers the development of AAP in 7-10% of patients with ALL, with more than half of those patients developing pancreatic necrosis. CalciMedica believes that the CRSPA trial has defined an optimal pediatric dose and plans to meet with the U.S. Food and Drug Administration in the first half of 2023 to determine the path forward for a potential accelerated approval of Auxora. Details of the CRSPA trial are available on clinicaltrials.gov (NCT04195347).
"I'm extremely pleased to announce this proposed merger with Graybug, which comes at a pivotal time for our company," said Rachel Leheny, Ph.D., Chief Executive Officer of CalciMedica. "This transaction will provide us with the financial strength to advance the development of our lead candidate, Auxora, in life-threatening inflammatory illnesses. We have multiple value-driving milestones expected over the next 12 months, including data from our Phase 2b CARPO clinical trial in patients with AP and a potential path to accelerated approval for Auxora in AAP. At CalciMedica, we are focused on delivering novel therapies that target CRAC channel inhibition to underserved patients with life-threatening inflammatory diseases for which no approved therapies exist. This transaction serves as a significant next step in the advancement of our important mission."
About the Proposed Transaction, Management and Organization
Graybug equity holders are expected to collectively own approximately 29% of the combined company, and pre-merger CalciMedica equity holders are expected to collectively own approximately 71% of the combined company, in each case, on a fully diluted basis using the treasury stock method. The percentage of the combined company that Graybug's equity holders will own as of the close of the transaction is subject to certain adjustments as described in the merger agreement, including an adjustment based on the amount of Graybug's net cash at closing.
Following the merger, the combined company will be headquartered in La Jolla, California and Rachel Leheny, Ph.D., will serve as Chief Executive Officer of the combined company. The merger agreement provides that the board of directors of the combined company will be composed of seven members, five selected by CalciMedica and two selected by Graybug.
The merger agreement has been unanimously approved by the boards of directors of both companies and is subject to the approvals by the stockholders of each company and other customary closing conditions.
Piper Sandler is serving as financial advisor and Fenwick & West LLP is serving as legal counsel to Graybug. Oppenheimer & Co. Inc. is serving as financial advisor and Cooley LLP is serving as legal counsel to CalciMedica.
Investor Conference Call Information
The companies will host a conference call and webcast presentation to discuss the proposed transaction as well as CalciMedica's technology and pipeline on Tuesday, November 22, 2022, at 8:00 a.m. ET. The live webcast and associated presentation can be accessed on the Investors and Media section of Graybug's website at https://investors.graybug.vision/news-events/events-presentations and CalciMedica's website at https://calcimedica.com/events, along with an archived replay following the live event. “
GLTA
That article is heinously irrelevant.
DWAC strong future ahead..,
GLTA
DWAC filing clearly stated “whether or not Trump runs for any political position”. Read filing you’ll agree this announcement is only positive for DWAC. Short term, long term, whatever…
GLTA
Why the DWAC dip today?
I like oyster & beer.
I like trump
Seriously 11/15 will make the big run up & UP…
GLTA
WTH Mullen down 16%???!!!
I see no buying just selling…
Leak of r/s?
GLTA
GDXU no news prior, during, nor even after, but 1:10 R/S effective 10/31/2022...
Nice...
Just keeps getting better...
GLTA
10/27/2022: Soligenix Invited to Submit BARDA Contract Proposal for Development of Thermostabilized Subunit Vaccines for Sudan Ebola and Marburg Viruses.
" - Emerging infectious diseases where no protective vaccines are currently available.
- SuVax™ targets Sudan ebolavirus, origin of a current disease outbreak in Uganda.
PRINCETON, N.J. , Oct. 27, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company has been invited by the Biomedical Advanced Research and Development Authority (BARDA) Division of Chemical, Biological, Radiological and Nuclear (CBRN) Medical Countermeasures to submit a full contract proposal for the development of single-vial, adjuvanted, heat stable subunit vaccines to prevent filovirus infection. This submission supports a potential multi-year, multi-million dollar contract to develop SuVax™ and MarVax™ vaccine candidates as medical countermeasures (MCM) for use in the event of a Sudan ebolavirus or Marburg marburgvirus outbreak.
Soligenix was invited to submit this proposal following a review of its white paper entitled, "SuVax™: A Safe and Thermostable Single-Vial Adjuvanted Subunit Vaccine with Rapid Onset Immunity to Sudan ebolavirus", which proposed development of SuVax™ through Phase 1 clinical studies in a $25 million program of work over 5 years. BARDA also requested that additional options be built into the full proposal including addressing a separate potential Marburg marburgvirus vaccine candidate, MarVax™, which has the potential to increase the value of the program. BARDA's mission is to develop and procure needed MCMs, including vaccines, therapeutics, diagnostics, and non-pharmaceutical countermeasures, against a broad array of public health threats, whether natural or intentional in origin.
In a non-human primate model of Sudan viral disease, SuVax™ demonstrated 100% protection four weeks after vaccination with a 3-dose series of SuVax™. Similar potency has been demonstrated for MarVax™. The development of these vaccines is part of an ongoing long-term collaboration with Soligenix's academic partner, the University of Hawai?i at Manoa. This work was partially supported by a $1.5 million Small Business Innovation Grant (#1R44AI157593-01) awarded to Soligenix and a grant to the University of Hawaii at Manoa (R01-AI132323) from the National Institute of Allergy and Infectious Diseases (NIAID).
"We are excited about the favorable review of our white paper by BARDA and by their invitation to submit a full contract proposal," stated Christopher J. Schaber, PhD, President & Chief Executive Officer of Soligenix. "Although a contract award is not guaranteed, we believe that we are well-positioned to receive BARDA development support for this indication allowing us to further demonstrate the growing body of compelling scientific evidence supporting our heat stable filovirus vaccine platform, including vaccine candidates directed towards Sudan ebolavirus and Marburg marburgvirus. This is particularly relevant given the outbreak of Sudan viral disease in Uganda for which there is no current protective vaccine available. We look forward to continued productive interactions with BARDA, NIAID and FDA as we move these programs forward."
The submission of a contract proposal is non-binding and does not guarantee the award of a BARDA contract. The contract award will require a favorable technical and scientific review by BARDA followed by negotiation of fair and reasonable contract terms.
About Filovirus Infection
Ebola Virus Disease is caused by one of six species of Ebolavirus, four of which are known to cause disease in humans, including its best-known member, Zaire ebolavirus (Ebola virus), with Sudan ebolavirus (Sudan virus) being the second-most common cause of human infection in this family. All species of ebolavirus belong to the Filoviridae family, a family that further contains the equally human pathogenic Marburg marburgvirus (Marburg virus). Filoviruses are believed to be harbored in various animal species in Africa, particularly bats, although the specific reservoir host for many of these viruses is still unknown. There have been several known Ebola and Marburg Virus Disease outbreaks since 1967, with the largest outbreak starting in 2014 in Western Africa, and involved over 26,000 confirmed/probable/suspected cases with an estimated death toll of over 11,000 people according to the Centers for Disease Control and Prevention (CDC). These numbers also include some cases of virus introduction and limited spread in Europe and the United States. Morbidity after viral infection is also significant, with surviving patients reporting symptoms including fatigue, memory problems, shortness of breath, sleep problems and joint pain for years after infection. Most recently, an outbreak of Sudan virus in Uganda has been declared, with containment activities underway.
Transmission of filoviruses requires direct contact with bodily fluids from an infected person or contact with infected animals. The mortality rates following filovirus infections are extremely high, and in the absence of wide availability of effective therapeutics, are affected by the quality of supportive care available with a focus on early initiation of treatment. Resolution of the disease largely depends on the patient's own immune system. There are limited treatment options for Ebola Virus Disease and no available treatments for Sudan Virus or Marburg Virus Disease, although steady progress has also been made in development of immunotherapeutics for filoviruses beyond Ebola virus. There are approved vaccines for Ebola virus, requiring stringent ultra-low cold-chain storage, but no efficacious vaccines are yet available for Marburg virus or Sudan virus.
Filoviruses are one of the virus families identified as having the ability to cause pandemics. On the heels of the COVID-19 pandemic the US government is accelerating its investment in pandemic preparedness, including having "the ability to rapidly make vaccines effective against any virus family". Specific initiatives have been spear-headed by the White House and Biden-Harris administration, as evidenced by the "American Pandemic Preparedness: Transforming Our Capabilities" white paper released in September 2021.
About John A. Burns School of Medicine, University of Hawai'i at Manoa
The John A. Burns School Medicine (JABSOM) at the University of Hawai?i at Manoa is one of the leading medical institutions and one of the most ethnically diverse institutions in the United States. For more than a decade, JABSOM has ranked in the top 10% of allopathic medical schools for graduate retention with one of our UH-sponsored residency programs. Hawai?i's cultural diversity and geographical setting affords JABSOM a unique research environment to excel in research directed at eliminating diseases that disproportionately affect people in Hawaii and the Pacific region. JABSOM faculty bring more than $40 million in extramural funds into the state, annually. In addition, JABSOM was the first U.S. medical school to create a clinical department dedicated to the health and well-being of an indigenous population, Native Hawaiians.
About Soligenix, Inc.
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (SGX301 or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With a successful Phase 3 study completed, regulatory approval is being sought and commercialization activities for this product candidate are being advanced initially in the U.S. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation including pediatric Crohn's disease (SGX203).
Our Public Health Solutions business segment includes active development programs for RiVax®, our ricin toxin vaccine candidate, and SGX943, our therapeutic candidate for antibiotic resistant and emerging infectious disease, and our vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax™, our vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax®. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA).
For further information regarding Soligenix, Inc., please visit the Company's website at https://www.soligenix.com and follow us on LinkedIn and Twitter at @Soligenix_Inc.
This press release may contain forward-looking statements that reflect Soligenix, Inc.'s current expectations about its future results, performance, prospects and opportunities, including but not limited to, potential market sizes, patient populations and clinical trial enrollment. Statements that are not historical facts, such as "anticipates," "estimates," "believes," "hopes," "intends," "plans," "expects," "goal," "may," "suggest," "will," "potential," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements, such as experienced with the COVID-19 outbreak. Soligenix cannot assure you that it will be able to successfully develop, achieve regulatory approval for or commercialize products based on its technologies, particularly in light of the significant uncertainty inherent in developing therapeutics and vaccines against bioterror threats, conducting preclinical and clinical trials of therapeutics and vaccines, obtaining regulatory approvals and manufacturing therapeutics and vaccines, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further funding to support product development and commercialization efforts, including grants and awards, maintain its existing grants which are subject to performance requirements, enter into any biodefense procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will not negatively affect its business, or that the U.S. Congress may not pass any legislation that would provide additional funding for the Project BioShield program. In addition, there can be no assurance as to the timing or success of any of its clinical/preclinical trials. Despite the statistically significant result achieved in the HyBryte™ (SGX301) Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma, there can be no assurance that a marketing authorization from the FDA or EMA will be successful. Notwithstanding the result in the HyBryte™ (SGX301) Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma and the Phase 1/2 proof-of-concept clinical trial of SGX302 for the treatment of psoriasis, there can be no assurance as to the timing or success of the clinical trials of SGX302 for the treatment of psoriasis. Further, there can be no assurance that RiVax® will qualify for a biodefense Priority Review Voucher (PRV) or that the prior sales of PRVs will be indicative of any potential sales price for a PRV for RiVax®. Also, no assurance can be provided that the Company will receive or continue to receive non-dilutive government funding from grants and contracts that have been or may be awarded or for which the Company will apply in the future. These and other risk factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, Soligenix's reports on Forms 10-Q and 10-K. Unless required by law, Soligenix assumes no obligation to update or revise any forward-looking statements as a result of new information or future events."
SOURCE Soligenix, Inc.
GLTA !
MULN shares for sale filing 10/17/2022:
"Filed pursuant to Rule 424(b)(4) - Registration No. 333-267913.
Prospectus Supplement No. 1 (To Prospectus dated October 17, 2022).
MULLEN AUTOMOTIVE INC. - 900,000,000 Shares of Common Stock.
This Prospectus Supplement No. 1 (this “Supplement”) supplements information contained in the prospectus dated October 17, 2022 (the “Prospectus”), relating to the resale by selling stockholders of Mullen Automotive Inc., a Delaware corporation, of up to 900,000,000 shares of our common stock, par value $0.001 per share (the “Common Stock”).
The Offered Shares consist solely of 23,000,000 shares of our Common Stock presently issued and outstanding, 350,000,000 shares of our Common Stock issuable upon conversion of our Series D Convertible Preferred Stock, par value $0.001 per share, and 527,000,000 shares of our Common Stock issuable upon exercise of outstanding warrants to purchase shares of our Common Stock.
This Supplement modifies, supersedes and supplements information contained in the Prospectus with respect to certain selling stockholders. This Supplement is incorporated by reference into, and should be read in conjunction with, the Prospectus. This Supplement is not complete without and may not be delivered or utilized except in connection with, the Prospectus, including any amendments or supplements thereto. Any information that is modified or superseded in the Prospectus shall not be deemed to constitute a part of the Prospectus, except as modified or superseded by this Supplement.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this Supplement is truthful or complete. Any representation to the contrary is a criminal offense.
The date of this Prospectus Supplement is October 19, 2022
SELLING STOCKHOLDERS
The number of maximum shares of Common Stock to be sold by each Selling Stockholder pursuant to the Prospectus included in the Prospectus was inadvertently listed incorrectly with respect to certain Selling Stockholders. Accordingly, the Selling Stockholders table is being amended in its entirety as follows:
Esousa Holdings, LLC(1) 78,184,454 / 325,287,281 / 55,184,454= 5.1%
Acuitas Capital, LLC(2) 56,941,087 / 318,909,099 / 56,941,087= 6.1%
Michael Friedlander(3) 725,824 / 1,594,546 / 725,824 *
Jess Mogul(4) 2,188,454 / 15,945,453 / 2,188,454 *
Jim Fallon(5) 1,000,000 / 1,972,727 / 1,000,000 *
Davis-Rice Pty Ltd(6) 18,474,651 / 159,454,534 / 18,474,651 = 2.1%
Digital Power Lending, LLC(7) 9,570,950 / 47,836,360 / 9,570,950 = 1.1%
* Represents less than 1%
(1) Consists of (i) 23,000,000 shares of Common Stock, (ii) 458 shares of Common Stock issuable upon conversion of 458 shares of Series C Preferred Stock, and (iii) 55,183,996 shares of Common Stock issuable upon exercise of Warrants, which may be deemed to be beneficially owned through Esousa Holdings, LLC by Michael Wachs, who serves as the sole Managing Member of Esousa Holdings, LLC. Does not include shares of Common Stock issuable upon conversion of that certain Secured Convertible Note and Security Agreement with Esousa Holdings LLC, which as of the date hereof had a principal amount outstanding of $12,945,914, and which converts into shares of Common Stock at a 5% discount to the lowest daily volume-weighted average price in the 10 trading days prior to conversion. The address for Esousa Holdings, LLC and Michael Wachs is 211 E 43rd St, 4th Fl, New York, NY 10017.
(2) Consists of 56,941,087 shares of Common Stock issuable upon exercise of Warrants, which may be deemed to be beneficially owned by Terren Peizer, who serves as the Chief Executive Officer of Acuitas Capital, LLC. The address for Acuitas Capital, LLC is 2120 Colorado Ave, Ste 230, Santa Monica, CA 90404.
(3) Consists of (i) 456,980 shares of Common Stock and (ii) 268,844 shares of Common Stock issuable upon exercise of Warrants. The address for Michael Friedlander is 46 Tarryhill Rd, Tarrytown, NY 10591.
(4) Consists of (i) 1 share of Common Stock and (ii) 2,188,453 shares of Common Stock issuable upon exercise of Warrants. The address for Jess Mogul is 347 W 87 St, Apt 2R, New York, NY 10024.
(5) Consists of 1,000,000 shares of Common Stock issuable upon exercise of Warrants. The address for Jim Fallon is 137 West 83rd St, Apt 5W, New York, NY 10024.
(6) Consists of 18,474,651 shares of Common Stock issuable upon exercise of Warrants. Shares held by Davis-Rice Pty Limited may be deemed to be beneficially owned by Timothy Davis-Rice, who serves as the Director of Davis-Rice Pty Limited. The address for Davis-Rice Pty Limited is 4 Murchison Street, Mittagong, NSW 2575, Australia.
(7) Consists of (i) 4,000,000 shares of Common Stock, (ii) 1,211,299 shares of Common Stock issuable upon conversion of 1,211,299 shares of Series C Preferred Stock, and (iii) 4,359,651 shares of Common Stock issuable upon conversion of 4,359,651 shares of Series D Preferred Stock, which may be deemed to be beneficially owned by David Katzoff, who serves as the Manager of Digital Power Lending, LLC. Digital Power Lending, LLC is a wholly owned subsidiary of Ault Global Holdings, Inc. The address for Digital Power Lending, LLC is 940 South Coast Drive, Ste 200, Costa Mesa, CA 92626."
GLTA
MULN 600m traded, and headed down end of day? Cmon !
Great MULN, but my avg is $2.64 !
GLTA
GDXU looks like giving us a little lower still...
No more powder to bring my $12 avg down, and definitely too risky next 3-4 Months?
GLTA
JNUG looks like giving us a little lower still...
No more powder to bring my $52 avg down, and definitely too risky next 3-4 Months?
GLTA
Shhhh.. let them play.
SNGX spring loaded
Seems MULN r/s news may have already leaked...
No reason for this low pps...
GLTA
F’n algo trading take downs…
Gotta crack down on that.
GLTA
SNGX 50% hair-cut in past few weeks (very low volume) ???
And they called my cell direct about Shareholder vote yesterday ?
GLTA
GRAY on 6mo High with no news...Yet... $3+ again soon?
It was less than one year ago !
GLTA
SNGX get's another $2.6m grant 9/12/2022:
"FDA Awards $2.6 Million Grant for Expanded Study of Soligenix's Hybryte(TM) for CTCL. 8:34 am ET September 12, 2022.
New York, New York--(Newsfile Corp. - September 12, 2022) - PCG Digital -- Late-stage biopharmaceutical company Soligenix, Inc. (NASDAQ: SNGX) has announced the award of a $2.6 million grant from the FDA to support a study of expanded HyBryteT treatment, including at-home usage. The FDA's support will give patients an opportunity to access Soligenix's HyBryteT therapy in an open-label setting. HyBryte is a novel skin directed photodynamic therapy for cutaneous T-cell lymphoma (CTCL), a rare skin disease and cancer.
GLTA
SNGX only 4,000 traded today???!!!
GLTA
WTH with MULN after great news???
SNGX less than 50k traded 2nd day in a row...
L2 is a joke.
When they gonna let SNGX loose? !!!
GLTA
Here we go JNUG... Gold on double bottom,,, so October looking UP for next 2 years?
GLTA
Here we go GDXU... Gold on double bottom,,, so October looking UP for next 2 years?
GLTA
DWAC ProxyVote extended 48hrs... I got it...
I just went to https://central.proxyvote.com/pv/web.
That worked! 3,000 DWAC votes FOR !
GLTA
About time for SNGX manipulation to stop & run UP again...
GLTA
And now 78 goes through?!!
That’s NOT what we want ?!
lost all at “Fox says”.
DWAC great opportunity!
It was removed. DWAC on the Up & UP
That was taken down as inaccurate info.
Not “fake”.
Just in accurate.
DWAC alive and well
DWAC following Biden’s market implosion
What's opinion of offered DWAC "redemption" ?
*I know $10 per share was always in the prospect - which is how much each stock holder gets in case the deal is off the table and SPAC is liquidated. So, they offer you to take these money in case you are not happy with the decision (suggested) to extended the timeline?
"Tender offer for DIGITAL WORLD
Status: Open for participation
This offer involves securities you own. Please review the terms carefully before choosing whether or not to participate. No action is required, but your securities may still be affected.
Cutoff date: 08/31/2022 7:00 PM ET
Expiration date: 09/01/2022 11:00 AM ET
Offered by: DIGITL WRLD ACQ CORP
- The information provided herein has been independently obtained or developed by various third-party firms through sources believed to be reliable. However, the accuracy, completeness or timeliness of the information is not guaranteed by Fidelity.
- Offer terms
Latest Update:08/25/2022 3:38 PM ETCUTOFF DATE: 08/31/2022 7:00 PM ET EXPIRATION DATE: 09/01/2022 11:00 AM ET
- Digital World Acquisition Corporation holders will be asked to consider and vote on an extension to the date by which the company must consummate a business combination, at the special meeting to be held on 9/6/22. The Company has set August 12, 2022, as the record date for voting in the meeting.
- Digital World is offering holders the right to redeem their shares for cash. The approximate price per share is $10.20, as disclosed in the proxy statement. There is no record date for redemption and holders do not have to vote in order to redeem.
- Warrant holders do not have voting or redemption rights.
Stockholders who own Digital World units must have the units split into the underlying common shares and warrants in order to tender the common shares. Processing of a unit split takes up to 3-4 business days.
- By electing to redeem your shares, you are attesting that are not acting in concert with, or as part of any group (as defined in Section 13d-3 of the Exchange Act) of any other shareholders with respect to shares of this common stock."
GLTA
...
...
....
Why does news always make MULN tank???!!!
DWAC gonna be a great story to remember!
GRAY ticking UP.
May be time.
GLTA
Frig... Already baked in ?
"Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On August 22, 2022, Transportation and Logistics Systems, Inc. (OTCQB:TLSS), (“TLSS” or the “Company”), received notice from OTC Markets Group that the company will be moved from the OTCQB market to OTC Pink (continuing under the same symbol, “TLSS”) before the next market open.
On May 23, 2022, the Company received notice from OTC Markets Group that as the Company’s bid price has closed below $0.01 for more than 30 consecutive calendar days, it no longer met the Standards for Continued Eligibility for OTCQB as per the OTCQB Standards, Section 2.3(2), which states that a company must “maintain proprietary priced quotations published by a Market Maker in OTC Link with a minimum closing bid price of $.01 per share on at least one of the prior thirty consecutive calendar days.”
The Company was informed further that, as per Section 4.1 of the OTCQB Standards, the Company was granted a cure period of 90 calendar days during which the minimum closing bid price for the Company’s common stock would have to be $.01 or greater for ten consecutive trading days in order to continue trading on the OTCQB marketplace. If that requirement was not met by August 21, 2022, the Company would be removed from the OTCQB marketplace.
The minimum closing bid price for the Company’s common stock was not $.01 or greater for any ten consecutive trading days prior to August 21, 2022. Consequently, OTC Markets Group is moving the Company to OTC Pink. The Company will likely be subject to only limited quotation on the OTC Pink market."
GLTA
I like DWAC. I like Trump, and personally believe he will lead this SPAC to great things.
GLTA
Spot on. DWAC is about investment.
What the Company May mean in the future.
GLTA